KemPharm Inc (NASDAQ:KMPH) shares saw unusually-strong trading volume on Friday . Approximately 1,837,282 shares were traded during mid-day trading, an increase of 964% from the previous session’s volume of 172,754 shares.The stock last traded at $6.00 and had previously closed at $5.26.
Several research analysts have weighed in on KMPH shares. Zacks Investment Research raised KemPharm from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Wednesday, November 15th. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st. Royal Bank of Canada set a $9.00 target price on KemPharm and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Finally, Canaccord Genuity set a $11.00 target price on KemPharm and gave the stock a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. KemPharm presently has an average rating of “Buy” and a consensus price target of $9.15.
The stock has a market cap of $87.94, a P/E ratio of -2.27 and a beta of -0.08. The company has a debt-to-equity ratio of -1.92, a current ratio of 7.56 and a quick ratio of 7.56.
In related news, EVP Daniel L. Cohen purchased 7,500 shares of the firm’s stock in a transaction dated Monday, November 27th. The stock was bought at an average price of $3.79 per share, for a total transaction of $28,425.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 22.80% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its stake in shares of KemPharm by 26.7% during the 4th quarter. Victory Capital Management Inc. now owns 162,077 shares of the specialty pharmaceutical company’s stock worth $656,000 after acquiring an additional 34,114 shares in the last quarter. C WorldWide Group Holding A S boosted its stake in shares of KemPharm by 14.1% during the 3rd quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after acquiring an additional 53,829 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its stake in shares of KemPharm by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock worth $3,672,000 after acquiring an additional 17,721 shares in the last quarter. Institutional investors own 36.33% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2018/02/25/kempharm-kmph-sees-strong-trading-volume.html.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.